Seelos therapeutics announces issuance of composition of matter patent in japan for sls-007

New york, dec. 6, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the japanese patent office (japanese patent number 6968839, titled: structure-based peptide inhibitors of alpha-synuclein aggregation), covering the composition of matter for sls-007, a potentially disease-modifying gene therapy focused on intracellular alpha-synuclein (Α-synuclein) aggregation in parkinson's disease (pd). seelos is currently conducting in vivo pre-clinical studies delivering sls-007 via an adeno-associated virus (aav) that is designed to target the non-amyloid component core (nacore) of Α-synuclein to inhibit abnormal aggregation and accumulation of the Α-synuclein protein in the brains of patients with parkinson's disease (pd).
SEEL Ratings Summary
SEEL Quant Ranking